Certolizumab Pegol for the Treatment of Crohn's Disease

Sandborn, William J.; Feagan, Brian G.; Stoĭnov, S; Honiball, Pieter J.; Rutgeerts, Paul; Mason, David; Bloomfield, Ralph; Schreiber, Stefan

doi:10.1056/nejmoa067594

Cited by 1,024 publications

(703 citation statements)

References 18 publications

Supporting

Mentioning

666

Contrasting

Unclassified

Order By: Relevance

“…Since the first double-blind, placebo-controlled trial with Infliximab (IFX) 2 numerous pivotal trials on the efficacy of IFX, Adalimumab (ADA) and Certzolizumab pegol (CTZ) in inducing and maintaining clinical response and remission and achieving mucosal healing have been published [2][3][4][5][6][7] .…”

Section: Introductionmentioning

confidence: 99%

Addressing current treatment challenges in Crohn's disease in real life: A physician's survey

Vavricka

Radivojevic²,

Manser³

et al. 2014

Digestive and Liver Disease

View full text Add to dashboard Cite

BACKGROUND: In recent years several trials have addressed treatment challenges in Crohn's disease. Clinical trials however, represent a very special situation. AIMS: To perform a cross-sectional survey among gastroenterologists on the current clinical real life therapeutic approach focussing on the use of biologics. METHODS: A survey including six main questions on clinical management of loss of response, diagnostic evaluation prior to major treatment changes, preference for anti-tumour necrosis factor (TNF) agent, (de-)escalation strategies as well as a basic section regarding personal information was sent by mail to all gastroenterologists in Switzerland (n=318). RESULTS: In total, 120 questionnaires were analysed (response rate 37.7%). 90% of gastroenterologists in Switzerland use a thiopurine as the first step-up strategy (anti-TNF alone 7.5%, combination 2.5%). To address loss of response, most physicians prefer shortening the interval of anti-TNF administration followed by dose increase, switching the biologic and adding a thiopurine. In case of prolonged remission on combination therapy, the thiopurine is stopped first (52.6%) after a mean treatment duration of 15.7 months (biologic first in 41.4%). CONCLUSIONS: Everyday clinical practice in Crohn's disease patients appears to be incongruent with clinical data derived from major trials. Studies investigating reasons underlying these discrepancies are of need to optimize and harmonize treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Addressing current treatment challenges in Crohn's disease in real life: A physician's survey

Vavricka

Radivojevic²,

Manser³

et al. 2014

Digestive and Liver Disease

View full text Add to dashboard Cite

show abstract

“…Patients who completed either of the PRECiSE 1 or 2 studies (which began in December 2003 and February 2004 respectively 18,19 ) were eligible for enrolment in the long-term extension study, PRECiSE 3 (ClinicalTrials.gov identifier NCT00160524), which continued until August 2012. For eligible patients, enrolment into the PRECiSE 3 study was based on individual patient decision and did not involve the study sponsor.…”

Section: Patientsmentioning

confidence: 99%

“…Enrolment criteria for PRECiSE 1 and 2 (initial studies) have been previously described. 18,19 Briefly, patients were ≥18 years of age and diagnosed with moderate-to-severe CD [Crohn's Disease Activity Index (CDAI) of 220-450 points scored over the week prior to the first study dose, suggesting a failure of conventional treatments]. Approximately 20% of patients were previously treated with, and had responded to, infliximab.…”

Section: Patientsmentioning

confidence: 99%

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Sandborn

Lee

Randall

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Humanization in theory may lead to a lower frequency of developing antidrug antibodies [59]. Certolizumab pegol is approved for use in Crohn's disease to achieve induction and maintenance of symptomatic response and improvement of quality-of-life measures [60][61][62][63][64][65][66]. Certolizumab pegol may differ from other TNFa antibodies since, due to its structure, it does not induce apoptosis in monocytes.…”

Section: Currently Available Therapeutic Antibodies In Digestive Disementioning

confidence: 99%

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

Sofia

Rubin

2017

Dig Dis Sci

View full text Add to dashboard Cite

The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn's disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

show abstract

Certolizumab Pegol for the Treatment of Crohn's Disease

Cited by 1,024 publications

References 18 publications

Addressing current treatment challenges in Crohn's disease in real life: A physician's survey

Addressing current treatment challenges in Crohn's disease in real life: A physician's survey

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

Contact Info

Product

Resources

About